Editorial - Archives of Dentistry (2019) Volume 1, Issue 1
The Dental and Oral Significance of Hutchinson-Gilford Progeria Syndrome
William James Maloney*
Department of Cariology and Comprehensive Care, NYU College of Dentistry, New York, USA
- *Corresponding Author:
- William James Maloney
Received date: November 08, 2018; Accepted date: November 22, 2018
Citation: Maloney WJ. The Dental and Oral Significance of Hutchinson-Gilford Progeria Syndrome. Arch Dent. 2018; 1(1):4-6.
Copyright: © 2018 Maloney WJ. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Like many other healthcare professionals who have contributed so much to the healing arts and sciences, Dr. Jonathan Hutchinson was a keen and astute observer of the human condition. Dr. Hutchinson was a 19th century surgeon who practiced in London. Hutchinson also served as president of the Royal College of Surgeons .
Hutchinson’s writings were prodigious and were surpassed by virtually no other author of his time as his bibliography contains almost 1,200 items .
In 1886, Hutchinson published “Case of congenital absence of hair, with atrophic condition of the skin and its appendages”. In this article, Hutchinson first described the genetic disorder which now bears his name- Hutchinson-Gilford progeria syndrome (HGPS) . This
syndrome was also later described by Gilford in 1904 .
HGPS is an extremely rare genetic disorder which is characterized by a series of signs and symptoms often associated with the elderly. In most cases, the genotypic basis for HGPS is a change in one nucleotide out of the three billion in the human genome .
Fortunately, there have been some recent advances in our understanding of HGPS but, the quantity of HGPS awareness and research must be increased to provide more substantial treatments for HGPS patients and, ultimately, a cure.
At any given time there are an estimated 200-250 individuals living throughout the world with HGPS . It is a very rare
disease with a birth prevalence of one in four million [5,6].
At birth the infant appears healthy . Physical features and ailments most often associated with the elderly start to develop in the first few years of life . Multiple organs and tissues replicate phenotypes which are associated with normal aging [5,7]. Physical signs and symptoms include prominent scalp veins, a beaked-nose and a loss of subcutaneous fat. Individuals with HGPS usually succumb to the disease in their early teenage years due to cardiovascular issues .The cause of HGPS is genetic. In most cases, glycine GGC changes into glycine GGT in codon 608 of the lamin A (LMNA) gene. This activates a cryptic splice donor site to produce abnormal lamin A. This, in turn, disrupts the nuclear membrane. The result is an alteration in transcription. The abnormal lamin A protein is known as progerin which makes the nucleus unstable leading to premature aging and disease .
Presently, there is a test for HGPS. Previously, a diagnosis had to be made on physical symptoms alone. These symptoms usually did not present themselves until the first or second year of the child’s life . The diagnostic test is genetic in nature and tests for an LMNA mutation and thus confirms a suspected diagnosis of HGPS .
There is presently no cure for HGPS but, there are new drugs on the horizon which provide a hopeful outlook. These drugs aim to treat the underlying genetic cause of the syndrome while providing an increased life expectancy for individuals with HGPS .
Cardiovascular conditions are closely monitored. Oftentimes, a low-dose aspirin therapy is recommended .
Lonafarnib, a Farnesyl Transferase inhibitor, has
exhibited some limited success in improving the various conditions associated with HGPS [14,15].
Another very interesting and promising recent research development is that the anti-diabetic drug metformin has been demonstrated to reduce progerin expression thus alleviating pathological phenotypes of HGPS .
The dentist plays a vital role in the medical team for HGPS as there are many traits of the syndrome which are of a dental and/or head and neck origin. Micrognathia is often present . This can lead to overcrowding and a
delayed loss of deciduous teeth.
Oftentimes, a high caries incidence is present in individuals with HGPS. As such, these patients must have frequent recall visits for both a re-examination of the teeth and associated hard and soft tissues of the oral cavity. Oral hygiene instructions must be reviewed at each dental visit with the patient and caregiver. The importance of meticulous oral hygiene must be continuously stressed. The dentist should incorporate fluoride therapies into the preventive protocol for HGPS patients. Of course, there are many fluoride therapies to choose from including fluoride varnishes, selfapplied fluorides (toothpastes, gels, mouth rinses) and professionally applied topical fluorides (higher-strength rinses, gels, foams). It is important to also stress that many bottled waters do not have optimal levels of fluoride .
HGPS patients typically experience a delayed eruption of teeth and root development. This is most likely due to the retrognathic position of the maxilla and mandible and insufficient jaw growth . Orthodontic therapy may therefore be indicated as there are no limitations in providing dental treatment to HGPS patients . It might be beneficial for any tooth movement to work in conjunction with an oral surgeon in order to ensure the efficacious and a traumatic removal of any over retained primary teeth which are in need of extraction.
Individuals with progeria are very special people on many different levels. This relatively small group of individuals deserves the support of researchers, healthcare practitioners and government agencies globally.
I call on the medical communities and funding agencies throughout the world to dramatically increase funding for HGPS research. Insurance companies and federal agencies must also act accordingly in a manner in which additional funds would be allotted for the treatment of HGPS and the enhancement of the quality of life for HGPS patients and their families. Corporate attention may be garnered by the very feasible hypothesis that HGPS accelerates a subset of the pathological changes  which is responsible for the normal aging process
thus providing almost limitless research opportunities
Indeed, I believe that these HGPS patients do hold the keys, within their mortal bodies, to the eternal mysteries of aging as they provide us with a rare and precious glimpse of the accelerated processes of natural aging. However, this should not be the primary reason we as healthcare providers and researchers and, more importantly, as merciful and benevolent human beings, must champion the cause of these brave children who suffer in silence.
Box 1-Dental manifestations [21,22]
• Secondary incisors located lingually and palatally
• Incomplete formation of roots of primary molars
• Tooth size/arch length discrepancies
• Delay in calcification of the crowns of the permanent
• Delayed tooth eruption of primary and secondary
• Calcification along the nerve fibers and the vascular
• Abnormal tooth formation
• Reticular atrophy of the pulp
• Irregularity in calcification of the crowns of the
• Agenesis of permanent teeth especially second
• Permanent molars often located in the ramus
• Narrow pulp chambers
• High caries incidence
• Severe crowding
Box 2-Craniofacial manifestation[23,24]
• Prominent scalp veins
• Craniofacial disproportion
• Perioral cyanosis
• Convex profile
• Limited range of motion
• Hypoplastic maxilla and mandible
• Retrognathic maxilla and mandible
• Class II skeletal malocclusion
• Small maxillary arch
• Comparative paucity of vertical growth
• Hypoplastic mandible
• Atrophy of alveolar process
• Small mouth
• Sparse to absent eyebrows and eyelashes
• Delayed closure of fontanelles and sutures
• No subcutaneous fat
• Relatively large tongue
• Sculpted beaked nose
• Prominent eyes
• Narrow and high palatal vault
• Short mandibular ramus
• Obtuse mandibular angle
• Prominent forehead and frontal bossing
• Large cranium.
- McKusick VA. The Gordon Wilson Lecture: The clinical legacy of Jonathan Hutchinson (1828-1913): syndromology and dysmorphology meet genomics. Trans Am Climatol Assoc. 2005;116:15-38.
- Kelly EC. Selections from the writing of Sir Jonathan Hutchinson. MedClassics. 1940;5:109-245.
- Hutchinson J. Case of congenital absence of hair, with atrophic condition of the skin and its appendages, in a boy whose mother had been almost wholly bald from alopecia areata from the age of six. Lancet. 1886;1:923.
- Gilford H. Ateleiosis and progeria: continuous youth and premature old age. Brit Med J. 1904;2:914-918.
- Coppede F. The epidemiology of premature aging and associated comorbidities. Clin Interv Aging. 2013;8:1023-1032.
- Pollex RL, Hegele RA. Hutchinson-Gilford progeria syndrome. Clin Genet. 2004;66:375-381.
- Gilford H. Progeria: a form of senilism. Practitioner. 1904;73:188-217.
- Coppede F. Premature aging syndrome. Adv Exp Med Biol. 2012;724:317-331.
- Progeria Research Foundation. What is the cause of progeria? Progeria Research Foundation. 2018.
- National Home Genome Research Institute. Learning about Progeria. Genome. 2018.
- Sinha JK, Ghosh S, Raghunath M. Progeria: A rare genetic premature ageing disorder. Indian J Med Res. 2014;139:667-674.
- Rehman NA, Rehman AA, Ashraf IN, Ahmed S. Can Hutchinson-Gilford progeria syndrome be cured in the future? Intractable Rare Dis Res.2015;4:111-112.
- Gonzalez JM, Pla D, Perez-Sala D, Andres U. A-type lamins and Hutchinson-Gilford progeria syndrome; pathogenesis and therapy. Front Biosc. 2011;3:1133-1146.
- Arancio W, Genovese SI, Pizzolanti G, Giordano C. Hutchinson-Gilford progeria syndrome: a therapeutic approach via adenoviral delivery of CRISP/cas genome editing system. J Genet Syndr Gene Ther. 2014;6:256.
- Ulrich NJ, Kieran MV, Miller DT, Gordon LB, Choy J. Neurologic features of Hutchinson-Gilford progeria syndrome after Lonafarnib treatment. Neurology. 2013;81:427-430.
- Egesipe AL, Blondel S, Lo Cicero A, Jaskowiak AL, Navarro C, DeSandre-Giovannoli A, Levy N, Peschanski M, Nissan X. Metformin decreases progerin expression and alleviates pathological defects of Hutchinson-Gilford progeria syndrome cells. Nature. 2016.
- Mehrez MAI, Mostafa MI. Hutchinson-Gilford progeria versus mandibuloacral dysplasia. Indian J Dermatol. 2014;59:211.
- American Dental Association. Oral health topics. Am Dental Assoc. 2018.
- Hazan-Molina H, Aizenbud D. Treatment considerations in Hutchinson-Gilford progeria syndrome: a case report. J Clin Pediatr Dent. 2015;39:172-178.
- Burtner CR, Kennedy BK. Progeria syndromes and ageing: what is the connection? Nat Rev Mol Cell Biol. 2010;11:567-578.
- Alves DB, Silva JM, Menezes TO, Cavaleiro RS, Tuji FM, Lopes MA, Zaiq AA, Coletta RD. Clinical and radiographic features of Hutchinson-Gilford progeria syndrome: a case report. World J Clin Cases. 2014;2:67-71.
- Domingo DL, Trujilo MI, Council SE, Meredith MD, Gordon LBN, Wu T, Introne WJ, Gahl WA, Hart TC. Hutchinson-Gilford progeria syndrome: oral and craniofacial phenotypes. Oral Dis. 2009;15:187-195.
- Maloney W. The integral role of the dentist in treating individuals with Hutchinson-Gilford progeria syndrome. WebMedCentral Aging Dentistry. 2010;1:WMC00446.
- Devi AS, Thokchom S, Devi AM. Children living with progeria. Nurse Care Open Acces J. 2017;3:00077.